Stock Comparison

ECOR vs LLY

electroCore, Inc. vs Eli Lilly and Co

The Verdict

ECOR takes this one.

Winner

ECOR

electroCore, Inc.

2.5

out of 10

Risk Trap

LLY

Eli Lilly and Co

0.5

out of 10

Distressed

Head-to-Head

$79M

Market Cap

$965.0B

N/A

P/E Ratio

52.6

-44.1%

Profit Margin

N/A

-235.8%

Return on Equity

N/A

Aggressive

Overall Risk

Moderate

2.5

DVR Score

0.5

The Deep Dive

ECOR2.5/10

electroCore exhibits strong operational execution, evidenced by Q1 2026 revenue of $9.6M, representing a 42.64% YoY increase, and its gammaCore device addresses a vast market for headache disorders with patented, non-invasive technology. This market potential and product strength are compelling. However, these positives are severely undermined by critical financial distress. The company faces pers...

Full ECOR Analysis

LLY0.5/10

Eli Lilly remains a pharmaceutical powerhouse with exceptional market leadership, especially driven by its GLP-1 agonist franchise (Mounjaro/Zepbound). The company possesses a robust R&D pipeline and substantial competitive advantages through intellectual property and scale. While LLY offers strong long-term growth and stability, its current market capitalization exceeding $1 trillion makes achiev...

Full LLY Analysis

Want More Comparisons?

Run any stock through our deep value analyzer.

Analyze Any Stock →

Not Financial Advice

This comparison is for educational purposes only. We are not financial advisors. Always do your own research and consult a qualified advisor before investing.